Gilead Sciences Inc. and Nurix Therapeutics Inc. announced a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted protein degradation drugs for patients with cancer and other challenging diseases.
June 2019 is a busy month for approval applications for the U.S. Food and Drug Administration as the regulatory agency has a slate of PDUFA dates.
Abbott’s Afinion HbA1c Dx assay was launched as the only rapid point-of-care test cleared by the U.S. Food and Drug Administration to aid healthcare professionals in the diagnosis of diabetes and the assessment of patients’ risk of developing the condition.
Pfizer Inc. struck a deal with an enterprise value of about $11.4 billion to buy Array BioPharma Inc. to expand the company’s portfolio of potentially lucrative cancer drugs.
U.S. drugmakers filed a lawsuit challenging a new government regulation that would require them to disclose the list price of prescription drugs in direct-to-consumer television advertisements.
Vancouver-based AbCellera and Gilead Sciences forged a collaborative agreement to discover and develop ultra-rare antibodies that can be used in the treatment of a number of infectious diseases.
San Francisco-based BlackThorn Therapeutics announced closing on a $76 million Series B financing round.
IBM, Merck and Walmart were chosen for a U.S. FDA pilot program that will explore using blockchain technology to improve the security of prescription drug supply and distribution.
Shares of Texas-based Savara Inc. were down more than 72 percent after the company announced that the experimental autoimmune alveolar pulmonary proteinosis (aPAP) treatment Molgradex failed to hit the primary endpoint in a late-stage study.
GlaxoSmithKline struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California.
